Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Artiva Biotherapeutics (ARTV) Receivables - Other (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Receivables - Other for 3 consecutive years, with $67000.0 as the latest value for Q4 2025.

  • For Q4 2025, Receivables - Other fell 54.11% year-over-year to $67000.0; the TTM value through Dec 2025 reached $67000.0, down 54.11%, while the annual FY2025 figure was $67000.0, 54.11% down from the prior year.
  • Receivables - Other hit $67000.0 in Q4 2025 for Artiva Biotherapeutics, down from $79000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $892000.0 in Q2 2024 and bottomed at $30000.0 in Q2 2025.
  • Average Receivables - Other over 3 years is $288000.0, with a median of $139000.0 recorded in 2024.
  • On a YoY basis, Receivables - Other climbed as much as 40.15% in 2025 and fell as far as 96.64% in 2025.
  • Artiva Biotherapeutics' Receivables - Other stood at $724000.0 in 2023, then crashed by 79.83% to $146000.0 in 2024, then tumbled by 54.11% to $67000.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $67000.0, $79000.0, and $30000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.